Keyphrases
Health Care Use
100%
Arthritis Patients
100%
Inflammatory Arthritis
100%
Health Care Costs
100%
GP2017
100%
Adalimumab Biosimilar
100%
Hospital Costs
75%
Biosimilar
75%
Denmark
50%
Adalimumab
50%
Axial Spondyloarthritis (AxSpA)
50%
Generalized Estimating Equations
50%
Psoriatic Arthritis
50%
Switcher
50%
Prescription Registry
25%
Rheumatoid Arthritis
25%
Biological Treatment
25%
Adjusted Analysis
25%
Treatment Monitoring
25%
Primary Sector
25%
DANBIO Registry
25%
Patient Education
25%
Observational Cohort Study
25%
Patient Concerns
25%
Prescription Drugs
25%
National Patient Registry
25%
Number of Outpatients
25%
Cost Savings
25%
Geographical Clusters
25%
Equation Model
25%
Monthly Fluctuations
25%
Pseudo-randomization
25%
Switching Costs
25%
Immunology and Microbiology
Inflammatory Arthritis
100%
Adalimumab
100%
Biosimilar Agent
100%
Psoriatic Arthritis
50%
Biochemistry, Genetics and Molecular Biology
Adalimumab
100%
Cohort Study
33%
Medicine and Dentistry
Inflammatory Arthritis
100%